Mucopolysaccharidosis Type

• EMA approval · 2024-10-17
  EMA Authorised: Aldurazyme (laronidase) — Sanofi B.V.

  The EMA authorised Aldurazyme (laronidase) for mucopolysaccharidosis type I, with Sanofi B.V. as the marketing authorisation holder (decisio…

• FDA approval · 2024-07-10
  FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)

  FDA approves a supplemental application for NAGLAZYME (galsulfase) by BioMarin Pharmaceutical Inc.

• FDA approval · 2023-12-14
  FDA Approved: ALDURAZYME — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for ALDURAZYME (Laronidase) submitted by Genzyme Corporation.

• FDA approval · 2019-12-04
  FDA Approved: ALDURAZYME — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for ALDURAZYME (laronidase) submitted by Genzyme Corporation.

• FDA approval · 2013-04-03
  FDA Approved: ALDURAZYME — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for Aldurazyme (laronidase) from Genzyme Corporation. This constitutes a supplemental approval of th…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2011-07-13
  FDA Approved: ALDURAZYME — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for Aldurazyme (laronidase) by Genzyme Corporation, updating labeling through a supplemental approva…

• FDA approval · 2009-08-25
  FDA Approved: ALDURAZYME — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for Aldurazyme (laronidase) submitted by Genzyme Corporation, indicating an FDA action related to an…

• FDA approval · 2009-05-20
  FDA Approved: ALDURAZYME — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for ALDURAZYME (Laronidase) from Genzyme Corporation, updating aspects of the approved product.